Superiority of ivermectin 1% cream over metronidazole 0·75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial

Taı̈eb, Alain; Ortonne, Jean Paul; Ruzicka, Thomas; Roszkiewicz, Jadwiga; Berth‐Jones, J.; Peirone, M H; Jacovella, Jean

doi:10.1111/bjd.13408

Cited by 149 publications

(151 citation statements)

References 20 publications

(38 reference statements)

Supporting

Mentioning

124

Contrasting

Unclassified

Order By: Relevance

“…1) [26]. The difference between the respective regimens for this outcome was slightly more notable among patients with severe (82.5 vs. 63.0 %) than moderate (85.4 vs. 77.9 %) rosacea at baseline.…”

Section: Versus Metronidazolementioning

confidence: 87%

“…The short-term efficacy of topical ivermectin 1 % cream in treating adults (aged C18 years) with moderate to severe papulopustular rosacea [as indicated by an Investigator Global Assessment (IGA) score of 3 or 4; Table 1] has been evaluated in three phase III trials of double-blind [25] or investigator-blind [26] design, denoted here as study 1, 2 and 3. These trials were of 12 or 16 weeks' duration and enrolled patients with 15-70 inflammatory facial lesions (papules/pustules).…”

Section: Short-term Usementioning

confidence: 99%

“…Eligible patients were randomized to receive ivermectin or vehicle in study 1 (n = 451 and 232) and 2 (n = 459 and 229) [25] and ivermectin or metronidazole in study 3 (n = 478 and 484) [26]. Across the three trials, patients had a mean age of 50-52 years and a mean inflammatory lesion count of 31-33; 76-83 % of patients had moderate rosacea, 17-24 % had severe rosacea and the majority of patients were White (C95 %).…”

Section: Short-term Usementioning

confidence: 99%

See 2 more Smart Citations

Ivermectin: A Review in Rosacea

Deeks

2015

Am J Clin Dermatol

View full text Add to dashboard Cite

Ivermectin 1% cream (Soolantra(®); Rosiver™; Izefla(®)) is a novel topical agent indicated for the once-daily treatment of inflammatory lesions of rosacea. Ivermectin is a derivative of the avermectin family of macrocyclic lactone parasiticides. It displays anti-inflammatory properties as well as broad-spectrum anti-parasitic activity, both of which may contribute to its efficacy in treating rosacea. In phase III trials of 12 or 16 weeks' duration in adults with moderate to severe papulopustular rosacea, once-daily ivermectin 1% cream improved the symptoms of rosacea (as per Investigator Global Assessment and inflammatory lesion count) and health-related quality of life versus vehicle, and was more effective than twice-daily metronidazole 0.75% cream in terms of these measures. Ivermectin 1% cream continues to provide benefit for up to 52 weeks of treatment, according to extension studies, and is well tolerated, with the most common treatment-related adverse events (skin burning sensation, pruritus, dry skin and skin irritation) each occurring with low incidence (<2%). Thus, ivermectin 1% cream is an effective and well tolerated option for the topical treatment of inflammatory lesions of rosacea, with the convenience of once-daily application.

show abstract

Section: Versus Metronidazolementioning

confidence: 87%

Section: Short-term Usementioning

confidence: 99%

Section: Short-term Usementioning

confidence: 99%

See 1 more Smart Citation

Ivermectin: A Review in Rosacea

Deeks

2015

Am J Clin Dermatol

View full text Add to dashboard Cite

show abstract

“…The latter, applied only once daily, has been proven to be more efficient and tolerable compared to a twice-daily applied 0.75% metronidazole cream [26]. Additionally, in February 2014, a 0.5% brimonidine tartrate gel for the treatment of flushing, which was previously only barely treatable, was approved [2, 27].…”

Section: Management Of Rosaceamentioning

confidence: 99%

Dermocosmetics for Use in Rosacea: Guideline of the Society for Dermopharmacy

Kresken¹,

Kindl²,

Wigger‐Alberti³

et al. 2018

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Rosacea is a widespread inflammatory skin disease that is chronically recurrent and affects predominately the central parts of the face. Affected individuals typically react to numerous cosmetics with redness, burning, and/or worsening of the complexion. Consequently, there is a high demand for dermocosmetics that do not provoke such reactions and are suitable for use in rosacea. The present guideline of the Society for Dermopharmacy describes the requirements that dermocosmetics for use in rosacea should meet. They include, inter alia, methods to prove the efficacy of and tolerance to these cosmetics, as well as the product documentation that the manufacturer or the distributing company should make available to professionals, like dermatologists and pharmacists, counseling patients with rosacea.

show abstract

“…Kolejne badanie porównujące skuteczność 1% kremu z iwermektyną (raz dziennie) z 0,75% kremem z metronidazolem (2 razy dziennie) stosowanymi przez 16 tygodni wykazało większą skuteczność iwermektyny niż używanego od lat metronidazolu. Po 16 tygodniach terapii całkowicie bez zmian skórnych było 34,9% pacjentów w grupie stosującej iwermektynę i 21,7% w grupie stosującej metronidazol [59]. Jeszcze ciekawsze okazały się wyniki ostatnio opu-blikowanych badań, w których stwierdzono bardzo korzystny wpływ iwermektyny na czas remisji w rosacea.…”

Section: Glikokortykosteroidyunclassified

Rosacea – new data on pathogenesis and treatment

Placek¹,

Wolska²

2016

View full text Add to dashboard Cite

StreSzczenieTrądzik różowaty jest częstą dermatozą, występującą przeważnie u kobiet i mającą istotny niekorzystny wpływ na jakość życia pacjentów. Obecnie przyjmuje się, że w jego przebiegu mogą przeważać zmiany rumieniowe lub zapalne, a w niektórych przypadkach przerostowe, niekoniecznie stanowiące kolejne etapy nasilenia choroby. Badania ostatnich lat wskazują, że podstawową rolę w rozwoju rosacea odgrywają zaburzona wrodzona odpowiedź immunologiczna i patologie w obrębie ukła-du naczyniowego skóry. Uwzględnia się również podłoże genetyczne i rolę skórnych, ale nie tylko, patogenów (np. Helicobacter pylori, Demodex). W związku z powyższym zalecane metody terapii uwzględniają działanie zarówno przeciwzapalne, jak i ukierunkowane na pasożyty skórne. Podstawowymi preparatami w terapii miejscowej są metronidazol, kwas azelainowy, antybiotyki, leki przeciwpasożytnicze, takie jak iwermektyna, oraz leki oddziałujące wybiórczo na zmiany naczyniowe. W cięższych przypadkach za leki z wyboru uznaje się obecnie tetracykliny, alternatywnie makrolidy, a w skrajnie ciężkich postaciach izotretynoinę. W związku z bezsprzeczną, co najmniej pogarszającą chorobę rolą promieniowania ultrafioletowego (UV) zaleca się rygorystyczną ochronę przed UV, a także -co również wynika z obserwacji klinicznych -odpowiednią dietę. Wraz z postępem techniki coraz większe znaczenie w leczeniu rosacea mają różnego typu terapie świetlne. AbStrActRosacea is a common dermatosis more prevalent in females, significantly impairing quality of life. Currently erythematous, papulo-pustular and phymatous subtypes are distinguished, which do not necessarily represent consecutive stages. Recent findings indicate in the pathogenesis of rosacea the role of the impaired innate immune system and vascular abnormalities. Additionally, the role of genetic and infectious factors is suggested. The therapy of rosacea is directed not only against inflammatory changes but also anti-parasitic. In topical treatment the most commonly used are metronidazole and azelaic acid. Other drugs are topical antibiotics, antiparasitic agents such as ivermectin and preparations directly influencing erythema. In more severe cases tetracyclines or macrolides are used, and in the most severe cases, isotretinoine. As ultraviolet light is a recognized trigger for rosacea, regular sunscreen use is necessary. Also, proper diet is indicated. Presently in the treatment of rosacea more and more techniques using different lights are employed.

show abstract

Superiority of ivermectin 1% cream over metronidazole 0·75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial

Abstract: Ivermectin 1% cream was significantly superior to MTZ 0·75% cream and achieved high patient satisfaction.

Cited by 149 publications

References 20 publications

Ivermectin: A Review in Rosacea

Ivermectin: A Review in Rosacea

Dermocosmetics for Use in Rosacea: Guideline of the Society for Dermopharmacy

Rosacea – new data on pathogenesis and treatment

Contact Info

Product

Resources

About